Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Q2 results

- PMLiVE

Moderna/Merck’s cancer vaccine shows promise in high-risk melanoma patients

Nearly 325,000 new cases of melanoma were diagnosed globally in 2020

- PMLiVE

Merck and Proxygen partner in deal worth up to $2.5bn

The companies will identify molecular glue degraders against multiple therapeutic targets

- PMLiVE

Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer

It is estimated there will be around 66,000 new cases of uterine cancer in the US this year

- PMLiVE

Medscape’s Commitment to Health Equity and Women’s Health

Women's health is a topic of increasing importance and interest among the medical community. Beyond impacting the individual patient, women's health is a public health issue in communities around the...

Medscape Education Global

- PMLiVE

Merck reports positive results for Keytruda combination in malignant pleural mesothelioma

The disease develops in the lungs and accounts for 75% of all cancerous mesothelioma cases

- PMLiVE

Merck signs $922m deal with Opko Health unit for Epstein-Barr vaccine candidate

There are no FDA approved vaccines for EBV, one of the most common human viruses

- PMLiVE

FDA approves intramuscular administration of Merck’s MMRV vaccines

Until now, the vaccines have only been administered via subcutaneous injection

- PMLiVE

Moderna/Merck’s skin cancer therapy given FDA breakthrough therapy designation

Nearly 325,000 new cases of melanoma were diagnosed globally in 2020

- PMLiVE

Merck and Ridgeback’s COVID-19 pill fails to prevent infection within households

Lagevrio is already approved to treat certain patients with COVID-19 in several markets

- PMLiVE

Merck reports positive results for Keytruda combination in phase 3 gastric cancer trial

Over one million new cases of gastric cancer were diagnosed globally in 2020

- PMLiVE

Merck KGaA and Aqilion AB partner in potential €960m deal

The companies will work together to develop small molecule inhibitors of the TAK1 protein

- PMLiVE

Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer

Endometrial cancer is the sixth most common cancer in women worldwide

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links